KeywordsANA, antinuclear antibody
DILE, drug-induced lupus erythematosus
SCLE, subacute cutaneous lupus erythematosus
SLE, systemic lupus erythematosus
TNF, tumor necrosis factor
adverse drug reaction
drug induced lupus
subacute cutaneous lupus
SYSTEMIC LUPUS ERYTHEMATOSUS
DRUG-INDUCED LUPUS ERYTHEMATOSUS
MetadataShow full item record
PublisherJAAD Case Reports
JournalJAAD Case Reports
AbstractDrug-induced lupus erythematosus (DILE) is a lupus-like syndrome temporally related to continuous drug exposure. DILE can be divided into systemic lupus erythematosus (SLE), subacute cutaneous lupus erythematosus (SCLE) and chronic cutaneous lupus.1 Hydrochlorothiazide was the first drug associated with SCLE in 1985,2 but at least 100 other agents have since been reported to induce/exacerbate SCLE, with terbinafine, tumor necrosis factor (TNF)-α inhibitors, antiepileptics, and proton pump inhibitors, the most frequently associated medications. We present a case of ustekinumab-induced SCLE in a patient being treated for psoriasis.
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 United States
- Drug-induced lupus: an update on its dermatologic aspects.
- Authors: Marzano AV, Vezzoli P, Crosti C
- Issue date: 2009 Oct
- Subacute cutaneous lupus erythematosus and systemic lupus erythematosus associated with abatacept.
- Authors: Tarazi M, Aiempanakit K, Werth VP
- Issue date: 2018 Aug
- Drug-induced lupus erythematosus.
- Authors: Vedove CD, Del Giglio M, Schena D, Girolomoni G
- Issue date: 2009 Jan
- Using the American College of Rheumatology (ACR) and Systemic Lupus International Collaborating Clinics (SLICC) criteria to determine the diagnosis of systemic lupus erythematosus (SLE) in patients with subacute cutaneous lupus erythematosus (SCLE).
- Authors: Tiao J, Feng R, Carr K, Okawa J, Werth VP
- Issue date: 2016 May
- Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agents.
- Authors: Dalle Vedove C, Simon JC, Girolomoni G
- Issue date: 2012 Dec
Showing items related by title, author, creator and subject.
Subacute cutaneous lupus erythematosus presenting as poikiloderma.Hughes, R; Loftus, B; Kirby, B; Department of Dermatology, Adelaide and Meath Hospital, Tallaght, Dublin,, Ireland. (2012-02-01)Subacute cutaneous lupus erythematosus (SCLE) is a recognised variant of lupus erythematosus (LE), which accounts for 10-15% of all cases of cutaneous LE, occurring most commonly in young to middle-aged white women. Diagnosis is based on the detection of anti-Ro/SS-A antibodies in the skin and serum, characteristic clinical and histological cutaneous involvement, and relatively mild systemic involvement. Several unusual variants of SCLE have been reported including erythrodermic SCLE, SCLE with vitiligo-like lesions, acral SCLE and bullous SCLE. Poikoilodermatous SCLE is a recognised but rare variant of SCLE. There are currently only two case reports, comprising five individual cases, in the literature. We present a case of SCLE in which the main clinical findings were an extensive photodistributed poikilodermatous rash and alopecia.
Fatigue and Activity Management Education for Individuals with Systemic Lupus Erythematosus.O'Riordan, Ruth; Doran, Michele; Connolly, Deirdre; 1 Occupational Therapy Department, St. James' Hospital, James' Street, Dublin 8, Ireland. 2 Rheumatology Department, St. James' Hospital, James' Street, Dublin 8, Ireland. 3 Trinity Centre for Health Sciences, Discipline of Occupational Therapy, St. James' Hospital, James' Street, Dublin 8, Ireland. (Wiley, 2017-01-01)Fatigue and Activity Management Education (FAME) is a six-week occupational therapy-led programme focusing on fatigue and stress management, exercise, nutrition, and joint protection. Each session consists of education and goal setting. To assess the impact of FAME on occupational participation and fatigue management. Three programmes were facilitated with twenty-one women with SLE. A mixed methods design was used. Quantitative data were collected using self-reported questionnaires administered before, immediately after, and eight weeks after intervention. Data were analysed using descriptive and nonparametric inferential statistics. Qualitative data were collected through focus groups and interviews. Thematic analysis was carried out on the qualitative data. There was a statistically significant improvement in depression as measured by the Hospital Anxiety and Depression Scale and categories of "burden to others" and "fatigue" in the LupusQoL. There were nonsignificant improvements in fatigue, occupational participation, self-efficacy, and anxiety. Participants reported an improved understanding of fatigue and the impact of stress on fatigue. They also identified self-management strategies they were using on a daily basis.
Sweet syndrome revealing systemic lupus erythematosus.Quinn, N; MacMahon, J; Irvine, A D; Lowry, C (Irish Medical Journal, 2015-02)Sweet Syndrome is an acute inflammatory skin eruption which is rare in children. We report a case of childhood Systemic Lupus Erythematosus (SLE) that presented with Sweet syndrome. This case is a unique presentation of a common disorder which provides a new facet for the differential diagnosis of SLE in children. It is also the first paediatric case to be reported in a Caucasian child.